Virologic Response and Survival Analysis of 281 HbsAg Treatment Naive Patients on Lamivudine Monotherapy in Sierra Leone

dc.contributor.author	Kangbai, Jia Bainga
dc.date.accessioned	2026-10-19T22:23:09Z
dc.date.issued	2017-10-06
dc.description.abstract	More than 350 million people are infected with Hepatitis B Virus (HBV) globally. The main aim of any chronic hepatitis B therapy is to prevent liver cirrhosis and its sequelae, including Hepatocellular Carcinoma (HCC). This is a cross sectional study that analysed medical records of 281 HBsAg seropositive patients in order to determine those factors that are associated with the reduction in the HBV viral load and the duration of HBV lamivudine monotherapy in order to attain a virological response.
dc.identifier.citation	Kangbai, J. B. (2017). Virologic Response and Survival Analysis of 281 HbsAg Treatment Naive Patients on Lamivudine Monotherapy in Sierra Leone. International Journal of Virology and AIDS, 4(1). https://doi.org/10.23937/2469-567x/1510029
dc.identifier.doi	10.23937/2469-567x/1510029
dc.identifier.uri	https://doi.org/10.23937/2469-567x/1510029
dc.identifier.uri	https://dspace.njala.edu.sl/handle/20.500.144402/1294
dc.language.iso	en
dc.relation.ispartof	International Journal of Virology and AIDS
dc.rights	CC BY
dc.subject	chronic hepatitis B
dc.title	Virologic Response and Survival Analysis of 281 HbsAg Treatment Naive Patients on Lamivudine Monotherapy in Sierra Leone
dc.type	Article

Files

Now showing 1 - 1 of 1

Name:: virologic-response-and-survival-analysis-of-281-hbsag-treatment-naive-patients-on-lamivudine.pdf
Size:: 740.58 KB
Format:: Adobe Portable Document Format
Description:: Published under CC BY.

Now showing 1 - 1 of 1